Press Release: Roche Decides to Terminate Cancer Collaboration With Epigenomics
BASEL, Switzerland, Dec. 15 -- Roche Diagnostics announced today that it has decided to terminate its 4-year collaboration with Epigenomics to develop prostate, breast, and colorectal cancer screening diagnostic tests based on Epigenomics' DNA methylation technologies. Roche determined that the colorectal cancer screening data presented by Epigenomics to date did not meet Roche criteria for development as in vitro diagnostic tests. About Roche and the Roche Diagnostics Division Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005 sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites www.roche.com and www.roche-diagnostics.com. NOTE: All trademarks used or mentioned in this release are legally protected by law.